Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2024-01-09 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene Presentation to JPMorgan Healthcare Conference 35 pages 5.0MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation focused on the company's clinical development programs, pipeline, market potential, and scientific background related to cancer immunotherapies. It includes investment highlights, clinical trial data, management team information, and product pipeline details. The presence of slides, disclaimers, and detailed business and clinical information aimed at investors strongly indicates this is an investor presentation. There is no indication that this is a formal regulatory filing like an annual or quarterly report, audit report, or earnings release. The document is not a transcript of a call, nor a voting or dividend announcement. It is not a legal or merger filing. The length and content are consistent with an investor presentation (IP).
2024-01-09 English
Imugene and NeoImmuneTech to Improve Cancer Treatments 4 pages 214.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing a strategic research collaboration between NeoImmuneTech and Imugene to evaluate cancer treatments. It describes the collaboration's scope, the involved products, and company backgrounds. There are no financial statements, regulatory certifications, voting results, or management changes. The content is a corporate announcement about a partnership and research plan, not a financial report, earnings release, or regulatory filing. The document length is 7,874 characters, which is sufficient for a detailed announcement but does not contain financial data or report content. Therefore, the document fits best into the category of a general regulatory announcement or corporate update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2023-12-11 English
Imugene to Present at Annual JPMorgan Healthcare Conference 3 pages 179.1KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement about Imugene Limited presenting at the 42nd Annual J.P. Morgan Healthcare Conference. It includes details about the event, presentation timing, webcast information, and company background. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, or other regulatory filings. The document is a public announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Given the content and context, the most appropriate classification is Investor Presentation (IP), as it relates to a presentation aimed at investors and the market, even though the actual presentation is scheduled for a future date and this is an announcement of that event. The document length is 4142 characters, which is relatively short but contains substantive information about the presentation event rather than just a brief notice or report publication announcement. Therefore, the best fit is Investor Presentation (IP) with high confidence.
2023-12-10 English
Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine 3 pages 138.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the European Patent Office's notification of intention to grant a patent for a cancer vaccine. It contains no financial data, no detailed financial performance, no management discussion of financial results, no voting results, no legal proceedings, no capital changes, and no executive compensation details. The document is a corporate announcement about intellectual property and patent status, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or others related to financial or governance reporting. It is a regulatory announcement informing the market about a patent grant status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-12-05 English
New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS 5 pages 194.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement detailing the commencement of a new Phase 2 clinical trial for a colorectal cancer vaccine by Imugene Limited. It includes information about the trial design, collaborators, objectives, and background on colorectal cancer. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The document is a corporate announcement about a clinical trial initiation, not a financial report or management discussion. It is not a report publication announcement since it contains substantive information about the trial itself rather than just announcing a report release. The content fits best under a general regulatory announcement category as it does not match any specific financial or governance filing types. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8737 characters) supports that it is a detailed announcement rather than a brief notice.
2023-12-05 English
Application for quotation of securities - IMU 8 pages 30.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. There is no financial performance data, management discussion, or regulatory certification. The document is clearly an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. This fits the definition of a Share Issue/Capital Change filing.
2023-12-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.